ICAM1 and non-small cell lung carcinoma: Nonetheless, in the ABIGAIL study [34], baseline and dynamic changes in plasma levels of ICAM-1 did not correlate with response to bevacizumab in 303 chemotherapy-naïve patients with non-small cell lung cancer who were treated with bevacizumab in combination with chemotherapy (carboplatin and gemcitabine or carboplatin and paclitaxel).